Latest Convertible Notes News

Osteopore Limited reported an 11% increase in revenue to $3.06 million for 2025, alongside a wider net loss of $3.72 million as it invests heavily in product development and regulatory compliance. The company also expanded its footprint with a new Singapore subsidiary.

InFocus Group Holdings Limited reported a 37% revenue increase to AUD 2.74 million for H1 FY26, alongside a substantial net loss of nearly AUD 3 million, as it invests in new digital asset and iGaming ventures.

Argent BioPharma reported a significantly reduced half-year loss of A$2.9 million, progressing a strategic acquisition to bolster its CannEpil drug pipeline and securing up to A$11 million in new funding.

RBR Group Limited narrowed its half-year loss to $588,746 as Mozambique LNG project activities resumed, underpinning cautious optimism amid ongoing funding challenges.

Halo Technologies Holdings Ltd posted a $17.4 million loss for 2025, widening from $14.5 million the previous year, as revenue fell 16%. The company completed a $3.9 million rights issue and announced a strategic pivot in its UK operations.

I Synergy Group Limited reported a 15.63% drop in revenue to AUD 0.81 million for FY2025, alongside a 21.5% increase in net loss to AUD 0.34 million, with auditors flagging going concern uncertainties.

CONNEQT Health reported a 40% revenue increase to $2.28 million for the half-year ending December 2025, driven by strong sales of its CONNEQT Pulse device and early subscription uptake. Despite narrowing its net loss by 14%, the company continues to navigate operational restructuring and funding challenges as it pivots towards a recurring revenue model.

Energy Technologies Limited reported a $5.63 million net loss for the half-year ending December 2025, with revenue down 53% as the company restructures and refocuses on renewable energy markets. Significant debt refinancing and board changes mark a critical phase for the industrial cable manufacturer.

Memphasys Limited has advanced its Felix™ System commercial rollout with key regulatory approvals and new international contracts, while trimming operating costs and narrowing losses in the first half of FY2026.

Hydrix Limited reported a 14% revenue decline and a sharp increase in net loss for H1 2026, raising concerns about its financial stability despite securing a major contract.

X2M Connect Limited has secured a $3 million capital raise to fund expansion into new markets and reduce debt, following a robust first half of FY26 marked by significant revenue and profit growth.

Paradigm Biopharmaceuticals reports a sharp rise in half-year losses as it intensifies investment in its pivotal Phase 3 trial for knee osteoarthritis, setting sights on a critical interim analysis in mid-2026. The company also expands its osteoarthritis pipeline and maintains strong funding amid a strengthening biotech sector.